{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 1824, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/NATJV1wYB8GC-AWewqSxF50pKtAXE_7syaXmdL33xjQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wODY4MGE3NWZjYjMvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/1", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/epdbdKzDDTYtWRkOakk3a1R3H7OGem2DjBom3HoyzYY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wODY4MGE3NWZjYjMvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/hNvZVX2Tv6de3BQR51MqmtUzFRWGTMMU7uJETFCrCTE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wODY4MGE3NWZjYjMvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/eOoTxthA3tcqlqTwNpWOK-ThMC7xfgVWsi36fQrt0K4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wODY4MGE3NWZjYjMvcDAwMS5wbmc" }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/2", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "key_messages", "function": "summarize", "notes": "The slide uses a three-column layout to segment the portfolio. The bottom callout emphasizes the societal impact.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/3", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "key_takeaways", "function": "summarize", "notes": "Uses news clippings as social proof/authority citation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/4", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "other", "function": "establish_context", "notes": "The slide uses a dual-axis chart to visually suggest a causal link between vaccine rollout and reduced mortality.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/5", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart uses a visual annotation to highlight the incremental FCF in 2021 and 2022 relative to the 2020 baseline.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/6", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "peer_gap", "function": "expose_gap", "notes": "The chart uses a red vertical arrow to explicitly quantify the 132-point underperformance gap.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/7", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "valuation_reveal", "function": "show_valuation_bridge", "notes": "The chart uses a custom bridge structure to calculate total value lost.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/8", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-8", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "valuation_table", "function": "compare_peers", "notes": "The chart highlights LLY and NVO as outliers due to GLP-1 participation. Pfizer is shown at 10x, below the 14x peer median.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/9", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-9", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "The slide uses a structured list of four key problem areas (A, B, C, D) followed by a summary of the financial impact.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/10", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-10", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 10, "from": 10, "beatId": "7fb1724d-2843-4f1d-ac69-ab3718b0ea90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem (Identify pain)", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies Pfizer's market value decline as a key issue.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/11", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-11", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights Pfizer's position relative to a peer median of 46 drugs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/12", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-12", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses external validation to support a thesis about the company's strategic positioning.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/13", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-13", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "This slide is part of an activist investor presentation (Starboard Value) intended to expose management's past claims against current performance or strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/14", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-14", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a dialogue format between a GS Analyst and the CEO to highlight a specific strategic commitment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/15", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-15", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a historical Pfizer graphic to frame a critique of R&D productivity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/16", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-16", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "precedent_table", "function": "cite_precedent", "notes": "The slide uses a table to demonstrate historical management commitments to specific R&D milestones.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/17", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-17", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a screenshot of a Pfizer table to critique their 'Up to 15 in 5' program claims.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/18", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-18", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "preempt_rebuttal", "function": "expose_contradiction", "notes": "The slide uses a screenshot of a Pfizer investor presentation to frame the argument that management failed to deliver on its own stated goals.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/19", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-19", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a callout to emphasize the gap between actual performance and the blockbuster threshold, and includes a quote from a 10-K filing to support the divestment claim.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/20", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-20", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses a screenshot of a news article as evidence of a failed clinical trial.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/21", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-21", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "thesis_headline", "function": "analyze_data", "notes": "The slide uses a red double-headed arrow to emphasize the gap between the 2030 projection and the blockbuster threshold.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/22", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-22", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "other", "function": "analyze_data", "notes": "The slide uses a visual gap analysis to emphasize the shortfall against a market benchmark.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/23", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-23", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a highlighted excerpt from a third-party report to substantiate the claim of failure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/24", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-24", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses a direct quote/excerpt from a primary source to validate the claim of continued success.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/25", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-25", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "preempt_rebuttal", "function": "preempt_rebuttal", "notes": "The slide uses a series of callout boxes to present external validation of competitive pressure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/26", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-26", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses a direct citation from a company press release to establish a negative precedent or track record.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/27", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-27", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses a screenshot of a press release to establish historical context for the drug's success.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/28", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-28", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide uses a screenshot of a news article to provide external validation of a failed drug development program.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/29", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-29", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "quote_slide", "function": "cite_precedent", "notes": "The slide uses a dialogue format between an analyst and the CEO to frame the company's strategic priorities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/30", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-30", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a 'preempt_rebuttal' or 'expose_contradiction' strategy by showing original company claims and implying failure through the context of the activist's critique.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/31", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-31", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [ { "to": 31, "from": 11, "beatId": "70a41b1b-59a4-4dcf-8d45-92e3a16e689b", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate (Make it worse)", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document highlights various challenges facing Pfizer, including lack of internal innovation and poor capital allocation.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "Uses highlighted text within quotes to emphasize key claims.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/32", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-32", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "comparison_table", "function": "analyze_data", "notes": "The slide highlights the gap between internal management targets and external analyst consensus.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/33", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-33", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "villain_critique", "function": "name_villain", "notes": "Uses external analyst quotes to build a case against management's R&D execution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/34", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-34", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "before_after", "function": "analyze_data", "notes": "The chart highlights a 66% decrease in analyst expectations between March 2023 and October 2024.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/35", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-35", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide uses a grouped bar chart to contrast the revenue growth trajectories of two key competitors in the GLP-1 space.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/36", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-36", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/37", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-37", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights Pfizer's underperformance relative to peers, with a specific callout for 'PFE Excl. COVID'.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/38", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-38", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights that even when excluding COVID-related revenue, Pfizer (PFE) and PFE Excl. COVID underperform the peer median.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/39", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-39", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart uses a broken axis for the top two performers (NVO, LLY) to accommodate the scale.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/40", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-40", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/41", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-41", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "other", "function": "analyze_data", "notes": "The slide uses a bracket to aggregate the total M&A spend.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/42", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-42", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a stacked bar chart to visualize the revenue gap and contribution from various acquisitions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/43", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-43", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "comparison_table", "function": "analyze_data", "notes": "The chart highlights the 3.3x multiple for 'PFE Consolidated Deals (Mgmt)' as an outlier compared to the 10-year median of 2.4x.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/44", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-44", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "comparison_table", "function": "expose_gap", "notes": "The chart uses a stacked bar format to break down the revenue contributions from specific acquisitions (Seagen, Biohaven, GBT, Arena, ReViral).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/45", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-45", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "valuation_table", "function": "analyze_data", "notes": "The chart highlights two specific Pfizer deal data points (3.3x and 5.1x) against a 10-year industry median of 2.4x.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/46", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-46", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses a bar chart to visualize the delta between historical transaction multiples and current market valuation multiples.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/47", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-47", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses red annotations and arrows to draw a comparison between the acquisition cost and the projected revenue, framing it as a poor investment decision.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/48", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-48", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a direct quote from a press release to substantiate the claim of product withdrawal.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/49", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-49", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-84595e2c37a3", "docSlug": "08680a75fcb3", "documentTitle": "Pfizer Inc. (PFE)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "testimonial", "function": "expose_contradiction", "notes": "The slide uses external analyst sentiment to frame Pfizer's acquisition strategy as flawed.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-84595e2c37a3/50", "deckHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-84595e2c37a3#slide-50", "loopMatches": [ { "to": 73, "from": 10, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "28cefacd-d8d3-4ae9-ba09-ae3e05acdb07", "evidence": "The document highlights the potential costs of inaction for Pfizer, including continued underperformance and loss of value.", "position": 0, "objective": "What are the costs of inaction for Pfizer?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 71, "from": 11, "name": "Mece Breakdown", "slug": "40-mece-breakdown", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "matchId": "02f3fffa-109d-4115-8a3f-00c62628d55f", "evidence": "The document proposes a breakdown of Pfizer's challenges and potential solutions.", "position": 1, "objective": "How can Pfizer improve its performance?", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "confidence": 0.7, "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The chart compares actual historical performance against prior consensus estimates to demonstrate margin outperformance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/5", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-5", "loopMatches": [ { "to": 6, "from": 4, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "b5c65170-71b3-4e59-afcf-e70285afadcb", "evidence": "The document presents a pattern of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 0, "objective": "Can Salesforce improve its operational efficiency?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.7, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 5, "from": 4, "beatId": "71aeb1cf-4996-4c08-b2ff-3fa36b92a881", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem & Complication", "beatSlug": "consultants-gambit-problem-complication", "evidence": "The document highlights the problem of Salesforce operating below peer levels and the complication of improving operational margins.", "position": 1, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 8, "from": 5, "beatId": "cfcb2898-21b5-4e3d-855a-d4b1720c929f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents evidence of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights the 'Rule of 50' metric, showing CRM's improvement compared to a prior period.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/6", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-6", "loopMatches": [ { "to": 6, "from": 4, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "b5c65170-71b3-4e59-afcf-e70285afadcb", "evidence": "The document presents a pattern of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 0, "objective": "Can Salesforce improve its operational efficiency?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.7, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "cfcb2898-21b5-4e3d-855a-d4b1720c929f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents evidence of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "thesis_headline", "function": "analyze_data", "notes": "The slide uses a stock performance chart to validate the thesis that strategic changes have driven shareholder value.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/7", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "cfcb2898-21b5-4e3d-855a-d4b1720c929f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents evidence of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "valuation_table", "function": "compare_peers", "notes": "The chart uses a broken axis for the higher multiples (ORCL, NOW).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/8", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-8", "loopMatches": [ { "to": 10, "from": 8, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b233ed97-e534-4fac-a6a4-118cdb325fed", "evidence": "The document implies the cost of inaction through its presentation of a compelling valuation and potential for improved revenue growth.", "position": 1, "objective": "What is the cost of not improving revenue growth and operational efficiency?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 8, "from": 5, "beatId": "cfcb2898-21b5-4e3d-855a-d4b1720c929f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "The document presents evidence of Salesforce's transformation and potential for improved revenue growth and operational efficiency.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 11, "from": 8, "beatId": "b651a060-443c-45f4-9482-2c0e614a0502", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document presents a solution and approach for Salesforce to improve revenue growth and operational efficiency.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "thesis_headline", "function": "present_solution", "notes": "The slide uses a central hub-and-spoke diagram to illustrate the Salesforce platform architecture.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/9", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-9", "loopMatches": [ { "to": 10, "from": 8, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b233ed97-e534-4fac-a6a4-118cdb325fed", "evidence": "The document implies the cost of inaction through its presentation of a compelling valuation and potential for improved revenue growth.", "position": 1, "objective": "What is the cost of not improving revenue growth and operational efficiency?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 11, "from": 8, "beatId": "b651a060-443c-45f4-9482-2c0e614a0502", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document presents a solution and approach for Salesforce to improve revenue growth and operational efficiency.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "peer_gap", "function": "expose_gap", "notes": "Uses waterfall-style bridge charts to show historical improvement and remaining gap to peer median.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/10", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-10", "loopMatches": [ { "to": 10, "from": 8, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b233ed97-e534-4fac-a6a4-118cdb325fed", "evidence": "The document implies the cost of inaction through its presentation of a compelling valuation and potential for improved revenue growth.", "position": 1, "objective": "What is the cost of not improving revenue growth and operational efficiency?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 11, "from": 8, "beatId": "b651a060-443c-45f4-9482-2c0e614a0502", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document presents a solution and approach for Salesforce to improve revenue growth and operational efficiency.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "scenario_table", "function": "propose_solution", "notes": "The slide uses a 'Rule of 50' framework (Growth % + Margin %) to argue for operational improvements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/11", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 11, "from": 8, "beatId": "b651a060-443c-45f4-9482-2c0e614a0502", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution & Approach", "beatSlug": "consultants-gambit-solution-approach", "evidence": "The document presents a solution and approach for Salesforce to improve revenue growth and operational efficiency.", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" }, { "to": 14, "from": 11, "beatId": "69c3ebfb-0112-48c7-8692-eb6c58fc27d9", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document concludes with the potential impact and next steps for Salesforce.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart uses a 'Rule of 50' framework, which is a common SaaS performance benchmark. It includes a 'PF CRM' (Pro Forma) bar to illustrate the target.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/12", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 11, "beatId": "69c3ebfb-0112-48c7-8692-eb6c58fc27d9", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document concludes with the potential impact and next steps for Salesforce.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "valuation_table", "function": "compare_peers", "notes": "The slide uses a 'Rule of 50' framework to justify a lower forward valuation multiple for Salesforce.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/13", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 11, "beatId": "69c3ebfb-0112-48c7-8692-eb6c58fc27d9", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document concludes with the potential impact and next steps for Salesforce.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622b-71dc-a6da-81546787160b", "docSlug": "5200b91eefc3", "documentTitle": "Salesforce, Inc. (CRM)", "authorId": "03_Starboard_Value", "authorName": "Starboard Value", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2024-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "cover", "function": "front_matter", "notes": "Includes the company logo and website URL.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622b-71dc-a6da-81546787160b/14", "deckHref": "/decks/019dd923-622b-71dc-a6da-81546787160b", "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-81546787160b#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 14, "from": 11, "beatId": "69c3ebfb-0112-48c7-8692-eb6c58fc27d9", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "The document concludes with the potential impact and next steps for Salesforce.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }